160 related articles for article (PubMed ID: 29525557)
1. Absence of a neutralizing antibody response to humanized cobra venom factor in mice.
Ing M; Hew BE; Fritzinger DC; Delignat S; Lacroix-Desmazes S; Vogel CW; Rayes J
Mol Immunol; 2018 May; 97():1-7. PubMed ID: 29525557
[TBL] [Abstract][Full Text] [Related]
2. Humanized cobra venom factor: structure, activity, and therapeutic efficacy in preclinical disease models.
Vogel CW; Finnegan PW; Fritzinger DC
Mol Immunol; 2014 Oct; 61(2):191-203. PubMed ID: 25062833
[TBL] [Abstract][Full Text] [Related]
3. Identification of functionally important amino acid sequences in cobra venom factor using human C3/Cobra venom factor hybrid proteins.
Hew BE; Fritzinger DC; Pangburn MK; Vogel CW
Toxicon; 2019 Sep; 167():106-116. PubMed ID: 31207349
[TBL] [Abstract][Full Text] [Related]
4. Hybrid proteins of Cobra Venom Factor and cobra C3: tools to identify functionally important regions in Cobra Venom Factor.
Hew BE; Wehrhahn D; Fritzinger DC; Vogel CW
Toxicon; 2012 Sep; 60(4):632-47. PubMed ID: 22609532
[TBL] [Abstract][Full Text] [Related]
5. Functional analysis of Cobra Venom Factor/human C3 chimeras transiently expressed in mammalian cells.
Kölln J; Matzas M; Jänner N; Mix T; Klensang K; Bredehorst R; Spillner E
Mol Immunol; 2004 May; 41(1):19-28. PubMed ID: 15140572
[TBL] [Abstract][Full Text] [Related]
6. Functional characterization of human C3/cobra venom factor hybrid proteins for therapeutic complement depletion.
Fritzinger DC; Hew BE; Thorne M; Pangburn MK; Janssen BJ; Gros P; Vogel CW
Dev Comp Immunol; 2009; 33(1):105-16. PubMed ID: 18760301
[TBL] [Abstract][Full Text] [Related]
7. Purification of native and recombinant cobra venom factor using thiophilic adsorption chromatography.
Kölln J; Braren I; Bredehorst R; Spillner E
Protein Pept Lett; 2007; 14(5):475-80. PubMed ID: 17584174
[TBL] [Abstract][Full Text] [Related]
8. Cobra venom factor: Structure, function, and humanization for therapeutic complement depletion.
Vogel CW; Fritzinger DC
Toxicon; 2010 Dec; 56(7):1198-222. PubMed ID: 20417224
[TBL] [Abstract][Full Text] [Related]
9. Structure and function of recombinant cobra venom factor.
Kock MA; Hew BE; Bammert H; Fritzinger DC; Vogel CW
J Biol Chem; 2004 Jul; 279(29):30836-43. PubMed ID: 15131128
[TBL] [Abstract][Full Text] [Related]
10. Recombinant cobra venom factor.
Vogel CW; Fritzinger DC; Hew BE; Thorne M; Bammert H
Mol Immunol; 2004 Jun; 41(2-3):191-9. PubMed ID: 15159065
[TBL] [Abstract][Full Text] [Related]
11. Identification of intermolecular bonds between human factor B and Cobra Venom Factor important for C3 convertase stability.
Hew BE; Pangburn MK; Vogel CW; Fritzinger DC
Toxicon; 2020 Sep; 184():68-77. PubMed ID: 32526239
[TBL] [Abstract][Full Text] [Related]
12. Humanized cobra venom factor decreases myocardial ischemia-reperfusion injury.
Gorsuch WB; Guikema BJ; Fritzinger DC; Vogel CW; Stahl GL
Mol Immunol; 2009 Dec; 47(2-3):506-10. PubMed ID: 19747734
[TBL] [Abstract][Full Text] [Related]
13. Humanized cobra venom factor: experimental therapeutics for targeted complement activation and complement depletion.
Vogel CW; Fritzinger DC
Curr Pharm Des; 2007; 13(28):2916-26. PubMed ID: 17979736
[TBL] [Abstract][Full Text] [Related]
14. Molecular isoforms of cobra venom factor-like proteins in the venom of Austrelaps superbus.
Rehana S; Manjunatha Kini R
Toxicon; 2007 Jul; 50(1):32-52. PubMed ID: 17412383
[TBL] [Abstract][Full Text] [Related]
15. Cobra venom factor and human C3 share carbohydrate antigenic determinants.
Grier AH; Schultz M; Vogel CW
J Immunol; 1987 Aug; 139(4):1245-52. PubMed ID: 2440948
[TBL] [Abstract][Full Text] [Related]
16. Complement depletion with humanized cobra venom factor in a mouse model of age-related macular degeneration.
Fritzinger DC; Dean R; Meschter C; Wong K; Halter R; Borlak J; St John WD; Vogel CW
Adv Exp Med Biol; 2010; 703():151-62. PubMed ID: 20711713
[TBL] [Abstract][Full Text] [Related]
17. Antigenic relationships between human and cobra complement factors C3 and cobra venom factor (CVF) from the Indian cobra (Naja naja).
Eggertsen G; Lundwall A; Hellman U; Sjöquist J
J Immunol; 1983 Oct; 131(4):1920-3. PubMed ID: 6194220
[TBL] [Abstract][Full Text] [Related]
18. Structural studies on the cobra venom factor: isolation, purification, crystallization and preliminary crystallographic analysis.
Sharma S; Jabeen T; Singh RK; Bredhorst R; Vogel CW; Betzel C; Singh TP
Acta Crystallogr D Biol Crystallogr; 2001 Apr; 57(Pt 4):596-8. PubMed ID: 11264593
[TBL] [Abstract][Full Text] [Related]
19. Complement and myoblast transfer therapy: donor myoblast survival is enhanced following depletion of host complement C3 using cobra venom factor, but not in the absence of C5.
Hodgetts SI; Grounds MD
Immunol Cell Biol; 2001 Jun; 79(3):231-9. PubMed ID: 11380675
[TBL] [Abstract][Full Text] [Related]
20. Molecular cloning and derived primary structure of cobra venom factor.
Fritzinger DC; Bredehorst R; Vogel CW
Proc Natl Acad Sci U S A; 1994 Dec; 91(26):12775-9. PubMed ID: 7809120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
